Biotech Values

[DewDiligence]

PYMX:

Sounds to me like they will want to partner with one of the LMWH companies - having an agent that can reverse a LMWH quickly would certainly help sales of that particular LMWH… if all the trials are with a particular LMWH, doctors would certainly be more comfortable with that particular labeled combination.

This is a far-fetched premise, IMO. For all practical purposes, the LMWH market consists of exactly one product: Lovenox, which could soon be available as a generic (:- ))

Fragmin and the other non-Lovenox LMWH’s are non-factors in the marketplace, and I consider it highly unlikely that these drugs could see meaningful commercial uptake this late in the game even if there were clinical data on their reversibility with PMX-60056.

In other words, there are zero “LMWH companies” who are logical partners for PMX-60056, IMO.